National Comprehensive Cancer Network



NCCN Oncology Research Program (ORP)
NCCN Enzalutamide Research Grant Opportunity Submit by April 27, 2015
Study Proposal Submission-NCCN RMS
ORP Recent News
ORP Affiliate Research Consortium
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
Specialized Imaging Research Consortium™ (SIRC)
ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

Updated Guidelines for Non-Small Cell Lung Cancer

The NCCN Clinical Practice Guidelines in Oncology™ for Non-Small Cell Lung Cancer have been updated and published on NCCN.org as Version.1.2010.

The updated NCCN Guidelines now include a description of maintenance therapy for patients with advanced or metastatic disease. This new section helps distinguish between recommended therapies for continuation maintenance versus switch maintenance.

Erlotinib has been added as a first-line treatment option for EGFR mutation positive patients with advanced or metastatic disease with a category 2A designation. Bevacizumab and cetuximab have been added as treatment options for continuation maintenance with a category 1 designation. Pemetrexed and erlotinib have been added as treatment options for switch maintenance with a category 2B designation and docetaxel has been added as a treatment option for switch maintenance with a category 3 designation.